Cargando…

Receptor conversion in metastatic breast cancer: a prognosticator of survival

OBJECTIVE: This retrospective study investigated the association between hormone receptor (HR) conversion and survival in breast cancer patients. METHODS: Estrogen receptor (ER) and progesterone receptor (PR) status (positive or negative) of primary tumors and of paired metastatic sites in 627 breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Xiangying, Song, Santai, Jiang, Ze-Fei, Sun, Bing, Wang, Tao, Zhang, Shaohua, Wu, Shikai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342130/ https://www.ncbi.nlm.nih.gov/pubmed/27655689 http://dx.doi.org/10.18632/oncotarget.12114

Ejemplares similares

Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer
por: Sun, Bing, et al.
Publicado: (2016)

A nomogram for predicting survival in patients with breast cancer brain metastasis
por: Huang, Zhou, et al.
Publicado: (2018)

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
por: Sun, Bing, et al.
Publicado: (2016)

Density of bone metastatic lesions increases after radiotherapy in patients with breast cancer
por: Wang, Qian, et al.
Publicado: (2019)

Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer
por: Sun, Bing, et al.
Publicado: (2016)

Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer
por: Liu, Chao, et al.
Publicado: (2016)

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
por: Liu, Yi, et al.
Publicado: (2013)

Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases
por: Xuan, Liang, et al.
Publicado: (2020)

Brain metastasis reirradiation in patients with advanced breast cancer
por: Huang, Zhou, et al.
Publicado: (2017)

A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease
por: Liu, Chao, et al.
Publicado: (2018)

Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients
por: Liu, Chao, et al.
Publicado: (2018)

Receptor conversion and survival in breast cancer liver metastases
por: Sundén, Marcus, et al.
Publicado: (2023)

Clinical relevance of receptor conversion in metastatic breast cancer: Case report
por: Silva, Diogo J., et al.
Publicado: (2022)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?
por: Wang, Qian, et al.
Publicado: (2020)

Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer: A SEER-based study
por: Liu, Jianjun, et al.
Publicado: (2017)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021)

Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker
por: Choe, Hun Jee, et al.
Publicado: (2019)

Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra‐central non‐small cell lung cancer
por: Cong, Yang, et al.
Publicado: (2019)

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer
por: Ye, Qing, et al.
Publicado: (2017)

Prediction of Survival Outcome Using Chuang's Prognostic Scale in Metastatic Breast Cancer
por: Mohammed, Amrallah A, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study
por: Jin, Xi, et al.
Publicado: (2015)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
por: He, Yang, et al.
Publicado: (2023)

Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report
por: Meng, Xiangying, et al.
Publicado: (2017)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature
por: Chamorro, Yolcar, et al.
Publicado: (2022)

Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer
por: Yang, Jian, et al.
Publicado: (2019)

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Zhang, Hui-Qiang, et al.
Publicado: (2021)

Receptor conversion in distant breast cancer metastases
por: Hoefnagel, Laurien DC, et al.
Publicado: (2010)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer
por: Einama, Takahiro, et al.
Publicado: (2017)

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
por: Yuan, Yang, et al.
Publicado: (2021)

Bilateral breast adenocarcinomas with EML4–ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
por: Liu, Chao, et al.
Publicado: (2016)

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer
por: Jin, Liang, et al.
Publicado: (2020)

Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study
por: Jiang, Xiaofan, et al.
Publicado: (2022)

Racial Disparities in Survival of Breast Cancer Patients After Surgery
por: Wang, Shuhan, et al.
Publicado: (2022)

Preserved miR-361-3p Expression Is an Independent Prognostic Indicator of Favorable Survival in Cervical Cancer
por: Liu, Shikai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_09ljfsa9gnkpo3io3hl03hir5m